ODAC Will Have Bigger Role At Avastin Hearing Than Previously Described
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells the Oncologic Drugs Advisory Committee it will have a voting role at the two-day hearing, in contrast with CDER's original expectation that the panel would provide advice and recommendations but not vote.